Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenx	$583.62 +2.9%	$625.68	$352.77 ▼ $678.21	$35.46B	0.6	293,196 shs	659,110 shs
MRNA Moderna	$27.72 +2.1%	$34.43	$26.32 ▼ $170.47	$10.72B	1.86	6.93 million shs	11.79 million shs
ONC Beigene	$274.78 +1.4%	$0.00	$126.97 ▼ $287.88	$27.11B	0.65	461,513 shs	736,892 shs
TAK Takeda Pharmaceutical	$14.98 +0.5%	$14.23	$12.58 ▼ $15.31	$47.66B	0.46	1.80 million shs	1.11 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenx	-4.19%	-6.35%	-9.22%	-7.79%	+42.73%
MRNA Moderna	-4.20%	-19.76%	-12.27%	-34.68%	-74.28%
ONC Beigene	-0.42%	+8.21%	-0.28%	+27,103,999,900.00%	+27,103,999,900.00%
TAK Takeda Pharmaceutical	+0.20%	-0.96%	+3.51%	+12.58%	+9.03%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenx	3.1366 of 5 stars	3.5	2.0	0.0	0.0	3.1	1.7	1.9
MRNA Moderna	4.353 of 5 stars	4.0	1.0	0.0	4.6	1.9	2.5	1.3
ONC Beigene	1.2702 of 5 stars	2.5	0.0	0.0	0.0	2.0	1.7	0.6
TAK Takeda Pharmaceutical	2.5255 of 5 stars	0.0	3.0	2.5	0.0	2.6	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenx	2.91	Moderate Buy	$687.00	17.71% Upside
MRNA Moderna	2.04	Hold	$59.00	112.84% Upside
ONC Beigene	3.00	Buy	$310.00	12.82% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRNA, TAK, ARGX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/17/2025	ARGX argenx	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/13/2025	ONC Beigene	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$259.00
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	ARGX argenx	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold
3/10/2025	ARGX argenx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$775.00 ➝ $1,100.00
3/4/2025	ARGX argenx	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$650.00 ➝ $680.00
3/3/2025	ONC Beigene	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$207.00 ➝ $320.00
2/28/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
2/28/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenx	$2.19B	16.19	N/A	N/A	$69.22 per share	8.43
MRNA Moderna	$3.20B	3.35	N/A	N/A	$28.33 per share	0.98
ONC Beigene	$3.81B	7.11	N/A	N/A	$37.10 per share	7.41
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.51 per share	4.27	$15.39 per share	0.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenx	-$295.05M	$12.59	N/A	53.79	N/A	-2.11%	-1.45%	-1.29%	5/8/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
ONC Beigene	-$881.71M	-$6.14	N/A	387.01	7.73	-25.94%	-25.12%	-14.95%	N/A
TAK Takeda Pharmaceutical	$994.06M	$0.40	37.45	9.08	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)

Latest MRNA, TAK, ARGX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/27/2025	Q4 2024	ARGX argenx	$0.98	$1.58	+$0.60	$11.79	$678.52 million	$761.22 million
2/27/2025	Q4 2024	ONC Beigene	-$0.88	-$1.43	-$0.55	-$1.43	$1.09 billion	$1.13 billion
1/30/2025	Q3 2025	TAK Takeda Pharmaceutical	$0.34	$0.42	+$0.08	$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenx	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.54%	-8.36%	132.50%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenx	N/A	8.53	7.88
MRNA Moderna	N/A	3.67	3.62
ONC Beigene	0.05	1.93	1.72
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenx	60.32%
MRNA Moderna	75.33%
ONC Beigene	48.55%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenx	2.43%
MRNA Moderna	11.00%
ONC Beigene	7.43%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenx	650	60.76 million	59.29 million	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
ONC Beigene	10,600	98.64 million	90.59 million	N/A
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

MRNA, TAK, ARGX, and ONC Headlines

Recent News About These Companies

Head-To-Head Review: Xenetic Biosciences (NASDAQ:XBIO) versus Takeda Pharmaceutical (NYSE:TAK)

April 2 at 1:36 AM | americanbankingnews.com

Takeda dedicated to advanced healthcare

April 1 at 3:04 AM | vir.com.vn

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

March 31 at 12:45 PM | zacks.com

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer

March 30 at 11:29 PM | msn.com

Takeda reaffirms patient-centric mission in Vietnam: GM

March 30 at 8:27 AM | tuoitrenews.vn

Why Wave Life Sciences Ltd.’s (WVE) Stock Is Down 10.08%

March 28, 2025 | aaii.com

Takeda Canada says Health Canada expands marketing authorization for HyQvia

March 28, 2025 | markets.businessinsider.com

Charles Schwab Investment Management Inc. Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 28, 2025 | marketbeat.com

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

March 27, 2025 | newswire.ca

Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy?

March 25, 2025 | marketbeat.com

Cell and gene therapy market set to grow at 44% CAGR through 2030, reveals GlobalData

March 25, 2025 | financialexpress.com

Global pharma giants double down on China, betting on long-term growth

March 24, 2025 | globaltimes.cn

Summit Global Investments Has $9.66 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 23, 2025 | marketbeat.com

69,083 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Boston Partners

March 23, 2025 | marketbeat.com

Natixis Advisors LLC Acquires 21,539 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 23, 2025 | marketbeat.com

BioLife invests $4M to recycle biohazardous plastic waste

March 21, 2025 | plasticsnews.com

Signaturefd LLC Raises Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 21, 2025 | marketbeat.com

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

March 19, 2025 | zacks.com

Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High - What's Next?

March 18, 2025 | marketbeat.com

Protagonist Therapeutics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

March 18, 2025 | miamiherald.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Lowered by Brandes Investment Partners LP

March 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Joby Aviation: From Prototype to Profitability
By Jeffrey Neal Johnson | March 11, 2025
View Joby Aviation: From Prototype to Profitability
5 Hot Stock Buys for Investors in April
By Thomas Hughes | April 1, 2025
View 5 Hot Stock Buys for Investors in April
Tesla Stock: Finding a Bottom May Take Time
By Chris Markoch | March 4, 2025
View Tesla Stock: Finding a Bottom May Take Time
Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
By Thomas Hughes | March 18, 2025
View Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Tariffs Won’t Stop These 3 Stocks From Rising
By Chris Markoch | March 5, 2025
View Tariffs Won’t Stop These 3 Stocks From Rising

MRNA, TAK, ARGX, and ONC Company Descriptions

argenx NASDAQ:ARGX

$583.62 +16.53 (+2.91%)

Closing price 04:00 PM Eastern

Extended Trading

$578.21 -5.41 (-0.93%)

As of 06:24 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Moderna NASDAQ:MRNA

$27.72 +0.56 (+2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$26.58 -1.14 (-4.11%)

As of 07:20 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Beigene NASDAQ:ONC

$274.78 +3.74 (+1.38%)

As of 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Takeda Pharmaceutical NYSE:TAK

$14.98 +0.08 (+0.54%)

Closing price 03:59 PM Eastern

Extended Trading

$14.72 -0.27 (-1.77%)

As of 06:21 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time